Hepatocyte growth factor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
==== 1.D Non-ribosomally synthesized channels ==== 1.D.1 The Gramicidin A Channel Family 1.D.2 The Channel-forming Syringomycin Family 1.D.3 The Channel-Forming Syringopeptin Family 1.D.4 The Tolaasin Channel-forming Family 1.D.5 The Alamethicin or Peptaibol Antibiotic Channel-forming Family 1.D.6 The Complexed Poly 3-Hydroxybutyrate Ca2+ Channel (cPHB-CC) Family 1.D.7 The Beticolin Family 1.D.8 The Saponin Family 1.D.9 The Polyglutamine Ion Channel (PG-IC) Family 1.D.10 The Ceramide-forming Channel Family 1.D.11 The Surfactin Family 1.D.12 The Beauvericin (Beauvericin) Family 1.D.13 DNA-delivery Amphipathic Peptide Antibiotics (DAPA) 1.D.14 The Synthetic Leu/Ser Amphipathic Channel-forming Peptide (l/S-SCP) Family 1.D.15 The Daptomycin (Daptomycin) Family 1.D.16 The Synthetic Amphipathic Pore-forming Heptapeptide (SAPH) Family 1.D.17 Combinatorially-designed, Pore-forming, β-sheet Peptide Family 1.D.18 The Pore-forming Guanosine-Bile Acid Conjugate Family 1.D.19 Ca2+ Channel-forming Drug, Digitoxin Family 1.D.20 The Pore-forming Polyene Macrolide Antibiotic/fungal Agent (PMAA) Family 1.D.21 The Lipid Nanopore (LipNP) Family 1.D.22 The Proton-Translocating Carotenoid Pigment, Zeaxanthin Family 1.D.23 Phenylene Ethynylene Pore-forming Antimicrobial (PEPA) Family 1.D.24 The Marine Sponge Polytheonamide B (pTB) Family 1.D.25 The Arylamine Foldamer (AAF) Family 1.D.26 The Dihydrodehydrodiconiferyl alcohol 9'-O-β-D-glucoside (DDDC9G) Family 1.D.27 The Thiourea isosteres Family 1.D.28 The Lipopeptaibol Family 1.D.29 The Macrocyclic Oligocholate Family 1.D.30 The Artificial Hydrazide-appended pillar[5]arene Channels (HAPA-C) Family 1.D.31 The Amphotericin B Family 1.D.32 The Pore-forming Novicidin Family 1.D.33 The Channel-forming Polytheonamide B Family 1.D.34 The Channel-forming Oligoester Bolaamphiphiles 1.D.35 The Pore-forming cyclic Lipodepsipeptide Family 1.D.36 The Oligobornene Ion Channel Family 1.D.37 The Hibicuslide C Family 1.D.38 The Cyclic Peptide Nanotube (cPepNT) Family 1.D.39 The Light-controlled Azobenzene-based Amphiphilic Molecular Ion Channel (AAM-IC) Family 1.D.40 The Protein-induced Lipid Toroidal Pore Family 1.D.41 The Sprotetonate-type Ionophore (Spirohexanolide) Family 1.D.42 The Phe-Arg Tripeptide-Pillar[5]Arene Channel (TPPA-C) Family 1.D.43 The Triazole-tailored Guanosine Dinucleoside Channel (TT-GDN-C) Family 1.D.44 The Synthetic Ion Channel with Redox-active Ferrocene (ICRF) Family 1.D.45 The Sonoporation and Electroporation Membrane Pore (SEMP) Family 1.D.46 The DNA Nanopore (DnaNP) Family 1.D.47 The Pore-forming Synthetic Cyclic Peptide (PSCP) Family 1.D.48 The Pore-forming Syringomycin E Family 1.D.49 The Transmembrane Carotenoid Radical Channel (CRC) Family 1.D.50 The Amphiphilic bis-Catechol Anion Transporter (AC-AT) Family 1.D.51 The Protein Nanopore (ProNP) Family 1.D.52 The Aromatic Oligoamide Macrocycle Nanopore (OmnNP) Family 1.D.53 The alpha, gamma-Peptide Nanotube (a,gPepNT) Family 1.D.54 The potassium-selective Hexyl-Benzoureido-15-Crown-5-Ether Ion Channel (HBEC) Family 1.D.55 The Porphyrin-based Nanopore (PorNP) Family 1.D.56 The Alpha-Aminoisobutyrate (Aib) Oligomeric Nanopore (AibNP) Family 1.D.57 The Lipid Electro-Pore (LEP) Family 1.D.58 The Anion Transporting Prodigiosene (Prodigiosene) Family 1.D.59 The Anion Transporting Perenosin (Perenosin) Family 1.D.60 The Alpha,Gamma-Cyclic Peptide (AGCP) Family 1.D.61 The Anionophoric 2,6-Bis(Benzimidazol-2-yl)Pyridine (ABBP) Family 1.D.62 The Bis-Triazolyl DiGuanosine Derivative Channel-forming (TDG) Family 1.D.63 The Peptide-based Nanopore (PepNP) Family 1.D.64 The Carbon Nanotube (CarNT) Family 1.D.65 The Pore-forming Amphidinol (Amphidinol) Family 1.D.66 The Helical Macromolecule Nanopore (HmmNP) Family 1.D.67 The Crown Ether-modified Helical Peptide Ion Channel (CEHP) Family 1.D.68 The Pore-forming Pleuronic Block Polymer (PPBP) Family 1.D.69 The Conical Nanopore (ConNP) Family 1.D.70 The Metallic (Au/Ag/Pt/graphene) Nanopore (MetNP) Family 1.D.71 The Synthetic TP359 Peptide (TP359) Family 1.D.72 The Chloride Carrier Triazine-based Tripodal Receptor (CCTTR) Family 1.D.73 The Mesoporous Silica Nanopore (SilNP) Family 1.D.74 The Stimulus-responsive Synthetic Rigid p-Octiphenyl Stave Pore (SSROP) Family
== Medical uses == Ciclosporin is indicated to treat and prevent graft-versus-host disease in bone marrow transplantation and to prevent rejection of kidney, heart, and liver transplants. It is also approved in the US for treating of rheumatoid arthritis and psoriasis, persistent nummular keratitis following adenoviral keratoconjunctivitis, and as eye drops for treating dry eyes caused by Sjögren's disease and meibomian gland dysfunction. In addition to these indications, ciclosporin is also used in severe atopic dermatitis, It has been used in severe rheumatoid arthritis and related diseases. Ciclosporin has also been used in people with acute severe ulcerative colitis and hives that do not respond to treatment with steroids.
The IDF is planning a number of technological upgrades and structural reforms for the future. Training has been increased with greater cooperation between ground, air, and naval units. The Ground Forces are phasing out the M-16 rifle in favor of the IWI Tavor variants, most recently the IWI Tavor X95 flat-top ("Micro-Tavor Dor Gimel"). The outdated M113 armored personnel carriers are being replaced by the new Namer APCs, with 200 ordered in 2014, as well as obtaining the Eitan AFV, and upgrading the IDF Achzarit APCs. The backbone of the Artillery Corps, the M109 howitzer, will be phased out in favor of a still-undecided replacement, with the ATMOS 2000 and Artillery Gun Module under primary consideration. The IDF is planning a future tank to replace the Merkava, which will be able to fire lasers and electromagnetic pulses, run on a hybrid engine, with a crew as small as two, will be faster, and will be better-protected, with emphasis on active protection systems such as the Trophy over armor. The Combat Engineering Corps assimilated new technologies, mainly in tunnel detection and unmanned ground vehicles and military robots, such as remote-controlled IDF Caterpillar D9T "Panda" armored bulldozers, Sahar engineering scout robot and improved Remotec ANDROS robots.
Comparative bullet-lead analysis was used by the FBI for over four decades, starting with the John F. Kennedy assassination in 1963. The theory was that each batch of ammunition possessed a chemical makeup so distinct that a bullet could be traced back to a particular batch or even a specific box. Internal studies and an outside study by the National Academy of Sciences found that the technique was unreliable due to improper interpretation, and the FBI abandoned the test in 2005. Forensic dentistry has come under fire: in at least three cases bite-mark evidence has been used to convict people of murder who were later freed by DNA evidence. A 1999 study by a member of the American Board of Forensic Odontology found a 63 percent rate of false identifications and is commonly referenced within online news stories and conspiracy websites. The study was based on an informal workshop during an ABFO meeting, which many members did not consider a valid scientific setting. The theory is that each person has a unique and distinctive set of teeth, which leave a pattern after biting someone. They analyze the dental characteristics such as size, shape, and arch form. Police Access to Genetic Genealogy Databases: There are privacy concerns with the police being able to access personal genetic data that is on genealogy services. Individuals can become criminal informants to their own families or to themselves simply by participating in genetic genealogy databases.
Sources: en.wikipedia.org
== Notable researchers == Roger Guillemin and Andrew W. Schally were awarded the Nobel Prize in Physiology and Medicine in 1977 for their contributions to understanding "the peptide hormone production of the brain"; these scientists independently first isolated TRH and GnRH and then identified their structures.
Economic rewards: in the case of the North American Free Trade Agreement (NAFTA), membership in the free trade agreement benefits the parties' economies. For example, Mexican companies are given better access to U.S. markets due to their membership. External actors can also contribute to economic rewards and fuel the attractiveness of IGOs – notably for developing countries. For example, external donor funding from the European Union to IGOs in the Global South. Political influence: smaller countries, such as Portugal and Belgium, who do not carry much political clout on the international stage, are given a substantial increase in influence through membership in IGOs such as the European Union. Also for countries with more influence such as France and Germany, IGOs are beneficial as the nation increases influence in the smaller countries' internal affairs and expanding other nations dependence on themselves, so to preserve allegiance. Security: membership in an IGO such as NATO gives security benefits to member countries. This provides an arena where political differences can be resolved. Democracy: it has been noted that member countries experience a greater degree of democracy and those democracies survive longer. Reasons for rejecting membership:
Subcutaneously by injection of methylcobalamin, a form of B12 Oral folinic acid A vitamin and mineral supplement that includes antioxidants, coenzyme Q10 and vitamins B Tetrahydrobiopterin Interestingly, recent DBPC studies have shown that N-acetyl-1-cysteine, a glutathione precursor supplement, is effective in improving the symptoms and behaviours associated with ASD. However, glutathione was not measured in these studies. Small, medium and large DPBC trials and open small and medium-sized clinical trials demonstrate that new treatments for children with ASD for oxidative stress are associated with improvements in baseline symptoms of ASD, sleep, gastrointestinal symptoms, hyperactivity, seizures and parental impression, sensory and motor symptoms. These new treatments include N-acetyl-l-cysteine, methylcobalamin with and without oral folinic acid, vitamin C, and a vitamin and mineral supplement that includes antioxidants, enzyme Q10, and B vitamins. Several other treatments that have antioxidant properties, including carnosine, have also been reported to significantly improve ASD behaviours, suggesting that treatment of oxidative stress could be beneficial for children with ASD. Many antioxidants can also help improve mitochondrial function, suggesting that clinical improvements with antioxidants could occur through a reduction in oxidative stress and an improvement in mitochondrial function. Some of these treatments can have frequent serious side effects such as bronchospasm.
=== Evolution === Genomic tRNA content is a differentiating feature of genomes among biological domains of life: Archaea present the simplest situation in terms of genomic tRNA content with a uniform number of gene copies, Bacteria have an intermediate situation and Eukarya present the most complex situation. Eukarya present not only more tRNA gene content than the other two kingdoms but also a high variation in gene copy number among different isoacceptors, and this complexity seem to be due to duplications of tRNA genes and changes in anticodon specificity. Evolution of the tRNA gene copy number across different species has been linked to the appearance of specific tRNA modification enzymes (uridine methyltransferases in Bacteria, and adenosine deaminases in Eukarya), which increase the decoding capacity of a given tRNA. As an example, tRNAAla encodes four different tRNA isoacceptors (AGC, UGC, GGC and CGC). In Eukarya, AGC isoacceptors are extremely enriched in gene copy number in comparison to the rest of isoacceptors, and this has been correlated with its A-to-I modification of its wobble base. This same trend has been shown for most amino acids of eukaryal species. Indeed, the effect of these two tRNA modifications is also seen in codon usage bias. Highly expressed genes seem to be enriched in codons that are exclusively using codons that will be decoded by these modified tRNAs, which suggests a possible role of these codons—and consequently of these tRNA modifications—in translation efficiency. Many species have lost specific tRNAs during evolution.
If the temperature is too low, the primer may bind imperfectly. If it is too high, the primer may not bind at all. A typical annealing temperature is about 3–5 °C below the Tm of the primers used. Stable hydrogen bonds between complementary bases are formed only when the primer sequence very closely matches the template sequence. During this step, the polymerase binds to the primer-template hybrid and begins DNA formation. Extension/Elongation: The temperature at this step depends on the DNA polymerase used; the optimum activity temperature for the thermostable DNA polymerase of Taq polymerase is approximately 75–80 °C (167–176 °F), though a temperature of 72 °C (162 °F) is commonly used with this enzyme. In this step, the DNA polymerase synthesizes a new DNA strand complementary to the DNA template strand by adding free dNTPs from the reaction mixture that is complementary to the template in the 5'-to-3' direction, condensing the 5'-phosphate group of the dNTPs with the 3'-hydroxy group at the end of the nascent (elongating) DNA strand. The precise time required for elongation depends both on the DNA polymerase used and on the length of the DNA target region to amplify. As a rule of thumb, at their optimal temperature, most DNA polymerases polymerize a thousand bases per minute. Under optimal conditions (i.e., if there are no limitations due to limiting substrates or reagents), at each extension/elongation step, the number of DNA target sequences is doubled.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.